Goodwin Advises the Placement Agents on $160 Million PIPE Financing

The Life Sciences team advised the placement agents, Jefferies, TD Cowen, Cantor, and LifeSci Capital, on a $160 million PIPE financing in connection with TriGemX Bio’s proposed business combination with TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company. The PIPE financing consists of common stock priced at $10.00 per share and, together with approximately $86 million held in TCGX Acquisition Corp.’s trust account, is expected to provide approximately $246 million in total gross proceeds to the combined company, assuming no redemptions by TCGX Acquisition Corp.’s public shareholders and before transaction costs. Upon closing, the combined company will operate as TriGemX Bio, Inc., and is expected to trade on Nasdaq under the ticker symbol TGEM. The proceeds are expected to support the Phase 3 clinical development of elismetrep, a potential first-in-class treatment for migraine, and commercial readiness activities ahead of a potential US launch.

Jefferies is the leading pure-play investment banking and capital markets firm, purpose-built and driven to deliver for clients.

TD Cowen offers a wide range of integrated capital markets products and services as a leading corporate and investment bank.

Cantor is a leading provider of fixed-income, equity, prime, asset management, and advisory products and services.

LifeSci Capital is a research-driven investment bank that focuses exclusively on emerging life science and healthcare companies.

The Goodwin team was led by Jocelyn Arel, Jeff Letalien, Sam Zucker, Deepa Rich, Susan Lee, Krupa Zachariah, Matt Wetzel, Olivia Uitto, Grace Kim, and Timbre Griffin.

For more information on the deal, please read the press release.